Hyperlipidemia Drug Market - RNA-Based Therapy Adoption Growing in Familial Hypercholesterolemia
Market Overview
The hyperlipidemia drug market is elevating as RNA-based therapy adoption grows in familial hypercholesterolemia management. The Hyperlipidemia Drug Market is projected to grow through 2030, driven by genetic lipid disorder treatment need, infrequent dosing preference, sustained LDL reduction demand, and specialty lipid clinic expansion supporting RNA-based therapy investment...
